CFHR3/CFHR1 deletion is associated with a decreased risk for the development of age-related macular degeneration (AMD) on the one hand, as well as with an increased risk for the development of atypical hemolytic uremic syndrome (aHUS), which, in the case of aHUS, seems to be partly explained by the appearance of anti-FH auto-antibodies [12–14]. Here, CFHR1 is linked to atypical hemolytic-uremic syndrome.